Trial Profile
A Phase I Open-Label, Dose-Escalation Study of Para-toluenesulfonamide Injection (PTS) Administered Intratumorally and Locally to Patients With Solid Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2018
Price :
$35
*
At a glance
- Drugs P-toluenesulfonamide (Primary)
- Indications Cancer metastases; Solid tumours
- Focus Adverse reactions
- Sponsors PTS International
- 03 Apr 2018 Planned End Date changed from 1 Jun 2019 to 1 Aug 2019.
- 03 Apr 2018 Planned primary completion date changed from 1 Mar 2019 to 1 May 2019.
- 03 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.